WVE logo

Wave Life Sciences Ltd. Ordinary Shares

WVE

WVE: WAVE Life Sciences Ltd is a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases. Wave aspires to develop best-in-class medicines across multiple therapeutic modalities using PRISM, the company's proprietary discovery and drug development platform that enables the precise design, optimization, and production of stereopure oligonucleotides. Driven by a resolute sense of urgency, the Wave team is targeting a broad range of genetically defined diseases so that patients and families may realize a brighter future.

more

Show WVE Financials

Chart and Financial Data provided by TradingView

All
Government
Consumer Interest
SEC Filings
ESG/Other
Congress Trading

Recent trades of WVE by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard
Whale Activity

Recently reported changes by institutional investors

Insider Trading

Quarterly net insider trading by WVE's directors and management

Corporate Lobbying

Government lobbying spending instances

  • $15,000 Jan 17, 2023 Issue: Health Issues
  • $15,000 Oct 17, 2022 Issue: Health Issues
  • $15,000 Jul 20, 2022 Issue: Health Issues
  • $15,000 Apr 20, 2022 Issue: Health Issues
  • $15,000 Jan 31, 2022 Issue: Health Issues
  • $15,000 Nov 02, 2021 Issue: Health Issues
  • $15,000 Jul 20, 2021 Issue: Health Issues
  • $15,000 Apr 23, 2021 Issue: Health Issues
  • $15,000 Jan 22, 2021 Issue: Health Issues
  • $15,000 Oct 19, 2020 Issue: Health Issues
  • $15,000 Jul 28, 2020 Issue: Health Issues
U.S. Patents

New patents grants

  • Patent Title: Compounds, compositions and methods for synthesis Aug. 08, 2023
  • Patent Title: Chiral control May. 09, 2023
  • Patent Title: Oligonucleotide compositions and methods thereof Apr. 25, 2023
  • Patent Title: Technologies for oligonucleotide preparation Mar. 21, 2023
  • Patent Title: Oligonucleotide compositions and methods of use thereof Mar. 14, 2023
  • Patent Title: Oligonucleotide compositions and methods of use thereof Mar. 07, 2023
  • Patent Title: Oligonucleotide compositions and methods thereof Mar. 07, 2023
  • Patent Title: Compositions and methods for phosphoramidite and oligonucleotide synthesis Aug. 09, 2022
  • Patent Title: Asymmetric auxiliary group Oct. 05, 2021
  • Patent Title: Oligonucleotides, compositions and methods thereof May. 25, 2021
  • Patent Title: Chiral design Oct. 27, 2020
  • Patent Title: Oligonucleotide compositions and methods thereof Jul. 28, 2020
  • Patent Title: Asymmetric auxiliary group Jun. 30, 2020
  • Patent Title: Chiral control Mar. 17, 2020
  • Patent Title: Oligonucleotide compositions and methods thereof Nov. 19, 2019
  • Patent Title: Oligonucleotide compositions and methods thereof Oct. 22, 2019
  • Patent Title: Chiral auxiliaries Oct. 01, 2019
  • Patent Title: Method for the synthesis of phosphorus atom modified nucleic acids Jun. 25, 2019
  • Patent Title: Nucleic acid prodrugs and methods of use thereof Jun. 04, 2019
  • Patent Title: Methods for the synthesis of functionalized nucleic acids May. 07, 2019
  • Patent Title: Asymmetric auxiliary group Jan. 01, 2019
  • Patent Title: Chiral design Dec. 25, 2018
  • Patent Title: Chiral control May. 29, 2018
  • Patent Title: Chiral control Feb. 06, 2018
  • Patent Title: Nucleic acid prodrugs and methods of use thereof Aug. 29, 2017
  • Patent Title: Methods for the synthesis of functionalized nucleic acids Mar. 28, 2017
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard
WallStreetBets

Number of mentions of WVE in WallStreetBets Daily Discussion

WVE News

Recent insights relating to WVE

CNBC Recommendations

Recent picks made for WVE stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in WVE

Corporate Flights

Flights by private jets registered to WVE